ReviewNature reviews. Rheumatology2020
Emerging pharmaceutical therapies for osteoarthritis.
Review in Nature reviews. Rheumatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 214 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
214 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Visualization and bibliometric analysis of 3D printing in cartilage regeneration.Frontiers in bioengineering and biotechnology · 2023Pooled it
- Hierarchical Nanorocket for spatially coordinated regulation of glycosaminoglycan deposition and metabolism in cartilage.Bioactive materials · 2027Article
- Redox-immune modulating gadolinium vanadate based nanozymes for osteoarthritis therapy.Materials today. Bio · 2026Article
- Soluble Nanomedicine Against Soluble Neurosensitizers to Effectively Relieve Osteoarthritis Pain and Joint Damage.Exploration (Beijing, China) · 2026Article
- The Anti-Osteoarthritis Effect of Medicinal and Edible Homologous Bioactive Components and Chinese Medicinal and Health Food Varieties.Nutrients · 2026Review
- A Thematic Narrative Review of Osteoarthritis Risk Factors Across the Female Life Course.International journal of molecular sciences · 2026Review
- IGF2BP3 Overexpression Accelerates Osteoarthritis Progression by Promoting Glycolysis via mThe Kaohsiung journal of medical sciences · 2026Article
- Decoction-derived bioactive nanoparticles of Lycopodium japonicum Thunb. attenuate knee osteoarthritis by regulating MAPK/ERK signaling.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Advances in carrier-free nanodrug delivery systems.Drug delivery and translational research · 2026Review
- Restoring Metabolic-Inflammatory Homeostasis: Curcumin's Multi-Layered Defense Against Chondrocyte Dysfunction.Metabolites · 2026Article
- Osteoarthritis: Epidemiology, Diagnosis, and Treatment.MedComm · 2026Review
- The effect of hyaluronic acid injection compared to corticosteroids injection in hand osteoarthritis: a systematic review and meta-analysis of randomized control trials.Korean journal of family medicine · 2026Article
- Light-Inducible Activation of FGFR3 Facilitates Chondrocyte Maturation.Cell proliferation · 2026Article
- Analysis of the Anti-inflammatory Effects of a Delivery System Based on Alginate Hydrogels Enriched with Bioactive Compounds from Marine Sponge Dysidea robusta.Applied biochemistry and biotechnology · 2026Article
- Osteoclast Heterogeneity in Osteoarthritis: From Single-Cell Microenvironments to Program-Specific Therapeutic Opportunities.International journal of molecular sciences · 2026Review
- Single-Cell Atlas of Subchondral Bone Marrow Lesions Reveals Proteostasis Dysfunction as a Druggable Mechanism for Early Osteoarthritis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- [Protective effect and mechanism of TSPAN9-mediated mitocytosis in interleukin-1β-induced rat chondrocyte senescence].Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2026Article
- Review
- cGAS-STING/HMGB1-mediated senescence induced by LRRK2 accelerates cartilage degeneration in osteoarthritis.Cell death & disease · 2026Article
- Photothermal reprogramming of synovial M1 macrophages reshapes the pro-inflammatory microenvironment to reverse temporomandibular joint osteoarthritis.Journal of nanobiotechnology · 2026Article
154 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prevalence of osteoarthritis (OA) and the burden associated with the disease are steadily increasing worldwide, representing a major public health challenge for the coming decades. The lack of specific treatments for OA has led to it being recognized as a serious disease that has an unmet medical need. Advances in the understanding of OA pathophysiology have enabled the identification of a variety of potential therapeutic targets involved in the structural progression of OA, some of which are promising and under clinical investigation in randomized controlled trials. Emerging therapies include those targeting matrix-degrading proteases or senescent chondrocytes, promoting cartilage repair or limiting bone remodelling, local low-grade inflammation or Wnt signalling. In addition to these potentially disease-modifying OA drugs (DMOADs), several targets are being explored for the treatment of OA-related pain, such as nerve growth factor inhibitors. The results of these studies are expected to considerably reshape the landscape of OA management over the next few years. This Review describes the pathophysiological processes targeted by emerging therapies for OA, along with relevant clinical data and discussion of the main challenges for the further development of these therapies, to provide context for the latest advances in the field of pharmaceutical therapies for OA.
Indexed as
Identifiers
33122845What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.